Overview

Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.